Lucas, Fabienne <br/><br/>
Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK/PLCG2 mutations.  [electronic resource] 

 -  Blood  06 2020 
 - 2192-2195 p.  digital 
<br/><br/> Publication Type: Letter; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1528-0020 
<br/><br/><label>Standard No.: </label>10.1182/blood.2019003722  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenine--analogs & derivatives<br/>Agammaglobulinaemia Tyrosine Kinase--genetics<br/>Aged<br/>Antineoplastic Agents--therapeutic use<br/>Bridged Bicyclo Compounds, Heterocyclic--therapeutic use<br/>Drug Resistance, Neoplasm--genetics<br/>Female<br/>Humans<br/>Leukemia, Lymphocytic, Chronic, B-Cell--drug therapy<br/>Male<br/>Middle Aged<br/>Molecular Targeted Therapy<br/>Mutation<br/>Phospholipase C gamma--genetics<br/>Piperidines--therapeutic use<br/>Proto-Oncogene Proteins c-bcl-2--genetics<br/>Sulfonamides--therapeutic use